EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Atomoxetine and spironolactone combine to reduce obstructive sleep apnea severity and blood pressure in hypertensive patients

Alan R Schwartz, Laura Herpel, Richard Bogan, Bruce Corser, Huy Pho, Luigi Taranto-Montemurro iD

Sleep and Breathing · 2024

DOI: 10.1007/s11325-024-03113-1 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Sleep and Breathing, 2024. Verfasst von Alan R Schwartz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary and Sleep Medical Group at SJMC, University of Maryland, Towson, MD, USA. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Hypertension, Atomoxetine Hydrochloride, Spironolactone. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Apnimed.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Norepinephrine reuptake inhibitors such as atomoxetine (ato) can improve OSA by increasing pharyngeal muscle activity. Mineralocorticoid antagonists such as spironolactone, may potentiate the reduction of OSA severity and reduce blood pressure. We evaluated whether adding spironolactone to atomoxetine (ato-spiro) improved responses in hypertensive OSA patients. METHODS: Twenty-one patients with an apnea-hypopnea index (AHI) between 10 and 50 events/h and a history of hypertension were recruited and crossed-over in random order to ato 80 mg and ato-spiro 80/50 mg for 1 week after a 3-day low dose run-in period. Two dropped out due to drug related side effects. Polysomnography and 24-hour blood pressure (BP) monitoring were performed at baseline and after each treatment period. RESULTS: AHI decreased on both ato and ato-spiro from a baseline median(IQR) of 20.3(18.8 to 28.5) to 8.2(7 to 13.1) and 6.2(5.7 to 14.1), respectively (p < 0.001 for both). Systolic BP (mmHg) fell by mean(95%CI) -4.5(-13.8 to 4.8, p = 0.33) on ato and - 10.3(-19.2 to -1.5, p = 0.02) on ato-spiro, and diastolic BP dropped by -3.0(-8.0 to 2.0, p = 0.23) on ato and - 5.0(-9.1 to -0.9; p = 0.02) on ato-spiro. Both ato and ato-spiro led to a significant shift from apnea to hypopnea predominance (p < 0.001), and significant reductions in hypoxic burden (p ≤ 0.001) and REM sleep (p ≤ 0.001). CONCLUSIONS: Both ato-spiro and ato alone decreased OSA severity similarly, but ato-spiro led to even greater, statistically significant and clinically meaningful falls in systolic and diastolic BP. BP reductions were likely due to ato-related improvements in upper airway patency and hypoxemia, and to spiro-related reduced fluid retention. These findings show promise for ato-spiro as an oral treatment for hypertensive OSA patients. REGISTERED AT CLINICALTRIALS.GOV: NCT04905979.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Apnea, ObstructiveHypertensionAtomoxetine HydrochlorideSpironolactoneCross-Over StudiesDrug Therapy, CombinationBlood PressureHumansMaleMiddle AgedFemaleAdrenergic Uptake InhibitorsPolysomnographyAdultAgedMineralocorticoid Receptor Antagonists

Stichwörter der Autor:innen

Aldosterone receptor antagonistOSA and hypertensionOSA combination treatmentOSA pharmacotherapy

Substanzen

Atomoxetine HydrochlorideSpironolactoneAdrenergic Uptake InhibitorsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Pulmonary and Sleep Medical Group at SJMC, University of Maryland, Towson, MD, USA.
  • Otorhinolaryngology Department, University of Pennsylvania, Philadelphia, PA, USA.
  • Otolaryngology Department, Vanderbilt University, Nashville, TN, USA.
  • Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Bogan Sleep Consultant, Columbia, SC, USA.
  • Intrepid Research, Cincinnati, OH, USA.

ORCID-Profile: Luigi Taranto-Montemurro

Förderung

  • Apnimed

Zitieren

APA

Schwartz, A. R., Herpel, L., Bogan, R., Corser, B., Pho, H., & Taranto-Montemurro, L. (2024). Atomoxetine and spironolactone combine to reduce obstructive sleep apnea severity and blood pressure in hypertensive patients. Sleep and Breathing. https://doi.org/10.1007/s11325-024-03113-1

Vancouver

Schwartz AR, Herpel L, Bogan R, Corser B, Pho H, Taranto-Montemurro L. Atomoxetine and spironolactone combine to reduce obstructive sleep apnea severity and blood pressure in hypertensive patients. Sleep and Breathing. 2024. doi:10.1007/s11325-024-03113-1

BibTeX
@article{Schwartz2024,
  author = {Schwartz, Alan R and Herpel, Laura and Bogan, Richard and Corser, Bruce and Pho, Huy and Taranto-Montemurro, Luigi},
  title = {Atomoxetine and spironolactone combine to reduce obstructive sleep apnea severity and blood pressure in hypertensive patients},
  journal = {Sleep and Breathing},
  year = {2024},
  doi = {10.1007/s11325-024-03113-1}
}
Kostenlos starten →